BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells

Industrial production of therapeutic monoclonal antibodies is mostly performed in eukaryotic-based systems, allowing posttranslational modifications mandatory for their functional activity. The resulting elevated product cost limits therapy access to some patients. To address this limitation, we con...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamain, Benoît, Brousse, Carine, Rainey, Nathan E., Diallo, Béré K., Paquereau, Clara-Eva, Desrames, Alexandra, Ceputyte, Jolita, Semblat, Jean-Philippe, Bertrand, Olivier, Gangnard, Stéphane, Teillaud, Jean-Luc, Chêne, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836820/
https://www.ncbi.nlm.nih.gov/pubmed/35148183
http://dx.doi.org/10.1126/sciadv.abl4363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836820/
https://www.ncbi.nlm.nih.gov/pubmed/35148183
http://dx.doi.org/10.1126/sciadv.abl4363

Ejemplares similares